Logo

People in the News: Dan Calvo, Erik Wallden, Sid Taubenfeld, Bill Dubiel

Oct 25, 2013
Premium

Gyros AB has appointed Dan Calvo president and CEO, replacing Erik Wallden.

Calvo was most recently president and CEO of Oncimmune USA. He was previously president and CEO of Assay Designs and Cellomics.

Sid Taubenfeld has joined Arrayit's board of directors.

Taubenfeld has served as an analyst for a number of Wall Street hedge funds, including Balyasny Asset Management, RH Capital, and PAW Partners. Additionally, Taubenfeld served as director of communications and strategic initiatives for Celsion Corp.

CyVek has appointed Bill Dubiel chief commercial officer.

Dubiel joins CyVek from Roche Tissue Diagnostics where he was vice president of sales. Before that he held senior positions at Bayer Healthcare, Chiron, and Ciba-Corning Diagnostics.

Filed under

Proteomics & Protein Research
proteomics
Arrayit
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.